Johanniskrauttee (Hypericum Perforatum)

• Johanniskrauttee is a herbal preparation that acts on neurotransmitter pathways associated with mood regulation.
• Mild to moderate depression: helps improve mood and emotional well‑being.
• Anxiety: may reduce nervous tension and promote a sense of calm.
• Sleep disturbances: supports more regular sleep patterns.

• Hypericum perforatum extracts inhibit the reuptake of serotonin, norepinephrine, and dopamine, thereby increasing the synaptic availability of these neurotransmitters. The combined effect modulates mood, anxiety, and sleep regulation pathways without directly stimulating receptor sites.

Adverse reactions reported with oral Hypericum perforatum tea are generally mild but can be clinically relevant.

Common Side Effects

• Gastrointestinal discomfort: mild nausea or stomach upset.
• Photosensitivity: increased skin sensitivity to sunlight.
• Fatigue: feeling of tiredness.
• Dizziness: occasional light‑headedness.

Serious or Rare Side Effects

• Serotonin syndrome: risk when combined with other serotonergic agents.
• Severe allergic reaction: rash, swelling, or breathing difficulty.
• Liver enzyme elevation: abnormal liver function test results.

• When considering Johanniskrauttee, several safety measures should be observed.
• Pregnancy: safety not established; avoid unless advised by a healthcare professional.
• Breastfeeding: insufficient data; consult a clinician before use.
• Concomitant serotonergic medication: risk of serotonin syndrome; monitor closely.
• Photosensitivity: limit sun exposure and use protective clothing or sunscreen.
• Psychiatric conditions: not a substitute for treatment of severe depression.
• Store at ambient temperature: keep in the original pack, protect from moisture and light.

Johanniskrauttee can affect the metabolism and efficacy of several drug classes.

Major Interactions (Avoid)

• SSRIs, SNRIs, MAO inhibitors: may cause serotonin syndrome.
• Tricyclic antidepressants: increased risk of serotonin toxicity.
• Anticoagulants (e.g., warfarin): may reduce anticoagulant effectiveness.
• Oral contraceptives: may lower plasma levels, increasing risk of breakthrough bleeding.

Moderate Interactions (Monitor Closely)

• Antiepileptic drugs (e.g., carbamazepine): may reduce plasma concentrations.
• Immunosuppressants (e.g., cyclosporine): possible decreased efficacy.
• Statins: potential reduction in drug levels.